Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboxyamidotriazole Orotate |
Synonyms | |
Therapy Description |
Carboxyamidotriazole orotate binds to and inhibits non-voltage-operated calcium channels and inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling (PMID: 29731337). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboxyamidotriazole Orotate | CTO | Carboxyamidotriazole orotate binds to and inhibits non-voltage-operated calcium channels and inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling (PMID: 29731337). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mutant | squamous cell carcinoma | sensitive | Carboxyamidotriazole Orotate | Phase I | Actionable | In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors including squamous cell carcinomas (tonsil) with PI3KCA and NRAS mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)). | detail... |
PIK3CA mutant | Advanced Solid Tumor | sensitive | Carboxyamidotriazole Orotate | Phase I | Actionable | In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors, including patients harboring PIK3CA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01107522 | Phase I | Carboxyamidotriazole Orotate + Temozolomide Carboxyamidotriazole Orotate | Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas | Active, not recruiting | USA | 0 |
NCT01989052 | Phase Ib/II | Lomustine Carboxyamidotriazole Orotate | Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | Terminated | USA | 0 |
NCT01954030 | Phase Ib/II | Bevacizumab Carboxyamidotriazole Orotate | Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | Terminated | USA | 0 |